RxDoctor Payments Data

Brittney McKendrick, APRN

Psychiatric/Mental Health · Hopkinsville, KYNPI 1174141840

Payments from drug & device makers

$1,730in general payments, 2019–2025

Across 56 payments — averaging $30.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$363
  • AbbVie$306
  • Otsuka America Pharmaceutical, Inc.$274
  • Vanda Pharmaceuticals Inc.$233
  • Neurocrine Biosciences, Inc.$162
  • E.r. Squibb & Sons, L.L.C.$135
  • plus $258 from 5 others

What the payments were for

  • Food & beverage$1,730100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,730 in reported general payments places this provider in the 70th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$8,984
Medicare patients
36
Services billed
142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate20$64,154
Abilify MaintenaAripiprazole22$60,793
VraylarCariprazine Hcl24$33,938
CaplytaLumateperone Tosylate20$33,322
RexultiBrexpiprazole13$19,936
Aripiprazole17$2,199
Ramelteon11$1,958
Bupropion XlBupropion Hcl55$1,478
Atomoxetine Hcl12$709
Buspirone Hcl73$634
Prazosin Hcl63$562
Quetiapine Fumarate70$537
Mirtazapine48$456
Trazodone Hcl42$417
Hydroxyzine Hcl46$384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$274$80,72935 claims
Johnson & JohnsonInvega Sustenna$363$64,15420 claims
AbbVieVraylar$306$33,93824 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$101$33,32220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Hopkinsville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →